Following the recommendations of the World Health Organization (WHO) for universal confirmation of all malaria infections before treatment, demand for malaria RDTs has grown substantially with an estimated 314 million tests procured in 2015, the vast majority of these tests designed to detect the Plasmodium falciparum histidine-rich protein 2 (HRP2) [1]. This evidence concerns the gene HDGFL2 and malaria.